Gadeta announces significant progress in advancing pipeline and TEG platform development
- Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for
solid tumors - Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program
GDT201
Utrecht, Netherlands and Boston, Mass., 15 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage
company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for
every cancer patient, today provides an update on its development pipeline and strategy.
